Pharmacokinetics of Carboplatin in Children and the Development of a Paediatric Dose Equation

  • A. H. Calvert
  • D. R. Newell
  • K. Balmanno
  • A. D. Pearson
  • L. Price
  • M. Kier


Since carboplatin first underwent clinical evaluation in 19811 it has established itself as important alternative to cisplatin. The most important advantage of carboplatin is that it has reduced non-haematological toxicities compared to cisplatin. The serious dose-limiting toxicities of cisplatin, nephrotoxicity and peripheral neuropathy, are virtually absent when conventional doses of carboplatin are used. Other toxicities such as emesis, ototoxicity and electrolyte loss are also reduced2.


Total Body Water Nonrenal Clearance Pretreatment Parameter Testicular Teratoma Carboplatin Clearance 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Calvert AH, Harland SJ, Newell DR, Siddik ZH, Jones AC, McElwain TJ, Shanti Raju K, Wiltshaw E, Smith IE, Baker JW, Peckham MJ, Harrap KR. Early clinical studies with cis-diammine-1,1-cyclobutanedicarboxylate platinum II. Cancer Chemother Pharmacol. 9:140–147, 1982.PubMedCrossRefGoogle Scholar
  2. 2.
    Canetta R, Rozencweig M, Carter SK: Carboplatin: The clinical spectrum to date. Cancer Treatment Reviews 12:125–136, 1985.PubMedCrossRefGoogle Scholar
  3. 3.
    Cleare MJ: Development of new new platinum coordination complexes: Overview, pp 213-215 in Platinum coordination complexes in cancer chemotherapy, Ed Miles P hacker and Irwin H Krakoff, Martinus Nijhoff Publishing 1983.Google Scholar
  4. 4.
    van der Vijgh WJF. Klein I. Protein binding of five platinum compounds: comparison of two ultrafiltration systems. Cancer Chemother Pharmacol. 18:129–132, 1986.PubMedCrossRefGoogle Scholar
  5. 5.
    Wiltshaw E. Ovarian trials at the Royal Marsden. Cancer Treat Rev. 12 suppl A(2):67–71 1985.PubMedCrossRefGoogle Scholar
  6. 6.
    ten Bokkel Huinink WW, van der Burg ME, van Oosterom AT, Neijt JP et al. Carboplatin in combination chemotherapy for advanced ovarian cancer. Cancer Treat Rev 15:9–15, 1988.PubMedCrossRefGoogle Scholar
  7. 7.
    Alberts DS, Mason-Liddil N. Carboplatin in the treatment of ovarian cancer. Semin Oncol 16 (2 suppl 5): 19–26, 1989.PubMedGoogle Scholar
  8. 8.
    Pater J for the Ovarian Cancer Trials committee of the NCIC. Cyclophosphamide/cisplatin versus cyclophosphamide/carboplatin in macroscopic residual ovarian cancer. Initial results of a National Cancer Institute of Canada clinical trials group trial. Proc Am Soc Clin Oncol abstract number 602, 1990.Google Scholar
  9. 9.
    Adams M, Kerby IJ, Rocker I, Evans A, Johansen K, Franks CR. A comparison of the toxicity and efficacy cisplatin and carboplatin in advanced ovarian cancer. Acta Oncol 28:57–60 1989.PubMedCrossRefGoogle Scholar
  10. 10.
    Smith IE, Harland SJ, Robinson BA, Evans BD, Goodhart LC, Calvert AH, Yarnold J, Glees PJ, Baker J. Ford HT. Carboplatin (JM8) A very active new cisplatin analogue in the treatment of small cell lung cancer. Cancer Treat. Rep. 69:43–46, 1985.PubMedGoogle Scholar
  11. 11.
    Craft AW and Pearson ADJ. Three decades of chemotherapy for childhood cancer. From ‘cure at any cost’ to ‘cure at least cost’. Cancer Surveys 8(3):605–630, 1989.PubMedGoogle Scholar
  12. 12.
    Harland SJ, Newell DR, Siddik ZH, Chadwick R, Calvert AH. Harrap KR. The pharmacokinetics of cis-diammine-1,1-cyclobutane dicarboxylate platinum (II) (CBDCA) in patients with normal and impaired renal function. Cancer Res. 44:1693–1697, 1983.Google Scholar
  13. 13.
    Egorin MJ, Van Echo DA, Tipping SJ et al, Pharmacokinetics and dose reduction of cis-diammine(1,1-cyclobutanedicarboxylato)platinum in patients with impaired renal function. Cancer Res 44:5432–5438, 1984.PubMedGoogle Scholar
  14. 14.
    Calvert AH, Newell DR, Gumbrell LA, O’Reilly S, Burnell M, Boxall FE, Siddik ZH, Judson IR, Gore ME, Wiltshaw E Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J. Clin. Oncol 7(11): 1748–1756, 1989.PubMedGoogle Scholar
  15. 15.
    Horwich A, Carboplatin in the treatment of testicular cancer: The Royal Marsden Hospital Testicular Tumour Unit Experience. pp53-62.Google Scholar
  16. 16.
    Chantier C, Garnett ES, Parsons V et al. Glomerular filtration rate measurement in man by a single injection method using 51Cr-EDTA. J Clin Sci 37:169–190, 1969.Google Scholar
  17. 17.
    Newell DR, Eeeles RA. Gumbrell LA et al. Carboplatin and etoposide pharmacokinetics in patients with testicular teratoma. Cancer Chemother Pharmacol. 23:367–372, 1989.PubMedCrossRefGoogle Scholar
  18. 18.
    Friis-Hansen B, Body water compartments in children: Changes during growth and related changes in body composition. Paediatrics 28:169–181, 1961.Google Scholar
  19. 19.
    Van Echo DA, Egorin MJ, Whitacre MY et al. Phase I clinical and pharmacological trial of carboplatin daily for 5 days. Cancer Treat Rep 68:1103–1114, 1984.PubMedGoogle Scholar
  20. 20.
    Koeller JM, Trump DL, Tutsch KD et al. Phase I clinical trial and pharmacokinetics of carboplatin by single monthly 30 minute infusion. Cancer 57:222–225 1986.PubMedCrossRefGoogle Scholar
  21. 21.
    Elferink F, van der Vigh WJF, Klein I et al. Pharmacokinetics of carboplatin after iv administration. Cancer Treat Rep 71:1231–1237, 1987.PubMedGoogle Scholar
  22. 22.
    Gaver RC, Colombo N, Grenn MD et al. The disposition of carboplatin in ovarian cancer patients. Cancer Chemother Pharmacol 22:263–270, 1988.PubMedCrossRefGoogle Scholar
  23. 23.
    Future Directions with Carboplatin: Can Therapeutic Monitoring, High-Dose and Growth Factors Expand the Spectrum Compared with Cisplatin? AH Calvert, DR Newell, ME Gore. In Carboplatin: Current Perspectives and future directions, Ed Ozols RF pub WB Saunders Company, Philadelphia 1991.Google Scholar

Copyright information

© Springer Science+Business Media New York 1991

Authors and Affiliations

  • A. H. Calvert
    • 1
  • D. R. Newell
    • 1
  • K. Balmanno
    • 1
  • A. D. Pearson
    • 1
  • L. Price
    • 1
  • M. Kier
    • 1
  1. 1.University of Newcastle upon TyneNewcastle upon TyneUK

Personalised recommendations